aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update.
Read more at globenewswire.com
